<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>When human peripheral blood lymphocytes (PBLs) from Epstein-Barr virus (EBV)-seropositive donors are injected intraperitoneally into <z:mp ids='MP_0002536'>SCID</z:mp> mice, EBV+ B cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> develop within weeks </plain></SENT>
<SENT sid="1" pm="."><plain>A preliminary report (Mosier, D </plain></SENT>
<SENT sid="2" pm="."><plain>E., R </plain></SENT>
<SENT sid="3" pm="."><plain>J </plain></SENT>
<SENT sid="4" pm="."><plain>Gulizia, S </plain></SENT>
<SENT sid="5" pm="."><plain>M </plain></SENT>
<SENT sid="6" pm="."><plain>Baird, D </plain></SENT>
<SENT sid="7" pm="."><plain>D </plain></SENT>
<SENT sid="8" pm="."><plain>Richman, D </plain></SENT>
<SENT sid="9" pm="."><plain>B </plain></SENT>
<SENT sid="10" pm="."><plain>Wilson, R </plain></SENT>
<SENT sid="11" pm="."><plain>I </plain></SENT>
<SENT sid="12" pm="."><plain><z:e sem="disease" ids="C0016632" disease_type="Disease or Syndrome" abbrv="">Fox</z:e>, and T </plain></SENT>
<SENT sid="13" pm="."><plain>J </plain></SENT>
<SENT sid="14" pm="."><plain>Kipps, 1989 </plain></SENT>
<SENT sid="15" pm="."><plain>Blood </plain></SENT>
<SENT sid="16" pm="."><plain>74(Suppl </plain></SENT>
<SENT sid="17" pm="."><plain>1):52a) has suggested that such <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> resemble the EBV-positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="18" pm="."><plain>The present work shows that generally the human (hu) PBL-<z:mp ids='MP_0002536'>SCID</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are distinct from Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and instead resemble lymphoblastoid cell lines (LCLs) generated by <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV-infection</z:e> of <z:mpath ids='MPATH_458'>normal</z:mpath> B cells in vitro in terms of: (a) their cell surface phenotype, with expression of B cell activation antigens and <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules, (b) <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype, and (c) <z:mp ids='MP_0001799'>viral</z:mp> phenotype, with expression of <z:hpo ids='HP_0000001'>all</z:hpo> the transformation-associated EBV latent proteins and, in a minority of cells, productive cycle antigens </plain></SENT>
<SENT sid="19" pm="."><plain>Indeed, in vitro-transformed LCLs also grow when inoculated into <z:mp ids='MP_0002536'>SCID</z:mp> mice, the frequency of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> outgrowth correlating with the in vitro growth phenotype of the LCL which is itself determined by the identity of the transforming virus (i.e., type 1 or type 2 EBV) </plain></SENT>
<SENT sid="20" pm="."><plain>Histologically the PBL-derived hu-<z:mp ids='MP_0002536'>SCID</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> resemble the EBV+ large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> that develop in immuno-suppressed patients and, like the human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, often present at multiple sites as individual monoclonal or oligoclonal foci </plain></SENT>
<SENT sid="21" pm="."><plain>The remarkable efficiency of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development in the hu-<z:mp ids='MP_0002536'>SCID</z:mp> model suggests that <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> involves direct outgrowth of EBV-transformed B cells without requirement for secondary genetic changes, and that selection on the basis of cell growth rate alone is sufficient to explain the monoclonal/oligoclonal nature of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> foci </plain></SENT>
<SENT sid="22" pm="."><plain>EBV+ large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the immunosuppressed may arise in a similar way </plain></SENT>
</text></document>